Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy

Area of Science:

• Hematology
• Pharmacology
• Genetics

Background:

• Sickle cell disease (SCD) is characterized by HbS polymerization, leading to vaso-occlusion and hemolysis.
• Fetal hemoglobin (HbF) inhibits HbS polymerization and is a therapeutic target in SCD.
• Hydroxyurea (HU) is a standard treatment for SCD, known to increase HbF production.

Purpose of the Study:

• To investigate the effects of HU treatment on HbF production and reticulocyte parameters in SCD patients.
• To compare laboratory findings between HU-treated and untreated SCD patients.
• To explore the relationship between reticulocyte indices and HbF/F-cell production.

Main Methods:

• Comparative laboratory analysis of 13 HU-treated SCD patients versus 33 untreated SCD patients.
• Measurement of hemoglobin concentration, red blood cell indices (MCV, MCH), reticulocyte parameters (count, immature count, MRV, MFI), HbF concentration, and F-cell percentage.
• Statistical analysis to identify correlations between parameters in HU-treated patients.

Main Results:

• HU-treated patients showed higher Hb, MCV, MCH, MRV, HbF concentration, F-cell percentage, and HbF/F-cell amount.
• Treated patients had lower reticulocyte count, immature reticulocyte count, MFI, and neutrophil count, suggesting reduced hemolysis.
• Significant correlations were found between MCV and HbF, MRV and HbF, and MRV and F-cell in HU-treated patients.

Conclusions:

• HU treatment in SCD patients leads to increased HbF and F-cell production, associated with reduced hemolysis.
• Increased Mean Reticulocyte Volume (MRV) in HU-treated patients may serve as an indirect indicator of F-cell production.
• Reticulocyte parameters assessed by hematological analyzers can be valuable tools for monitoring erythropoietic changes and HU therapy efficacy.